-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Shanghai Jiyu Medicine/Sun Pharma’s application for the listing of Sonny Deji Phosphate Capsules (trade name: Odomzo) was included in the priority review by CDE and started to be publicized for use in adult patients with locally advanced basal cell carcinoma (BCC) recurring after surgery or radiotherapy.
Sonidji Phosphate is an oral Smoothened (SMO) inhibitor developed by Novartis.
stem cell
Sony Deji phosphate as early as July 24, 2015 the US Food and Drug Administration Administration ( the FDA ) approved for marketing for the treatment of relapse after surgery or radiotherapy for locally advanced basal cell carcinoma, basal cell carcinoma or not surgery or radiation therapy.
Manage FDA
Odomzo’s FDA approval is based on a multi-center, double-blind, multi-cohort clinical study ((BOLT) in patients with locally advanced basal cell carcinoma (laBCC) (n=194) or metastatic basal cell carcinoma (mBCC) (n=36).
Basal cell carcinoma (BCC) is a common skin cancer that accounts for 80% of all non-melanoma cases.
Leave a message here